Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$7.37
-0.7%
$7.53
$3.68
$8.85
$275.70M0.65125,068 shs70,879 shs
Pharvaris N.V. stock logo
PHVS
Pharvaris
$22.30
-3.0%
$19.71
$11.51
$26.33
$1.17B-2.81192,452 shs167,398 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$15.74
+6.9%
$10.35
$8.58
$22.50
$1.36B0.742.71 million shs5.09 million shs
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$11.13
$10.55
$2.86
$11.40
$992.13M2.233.94 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
0.00%+1.80%-4.04%+6.97%+26.85%
Pharvaris N.V. stock logo
PHVS
Pharvaris
0.00%+10.83%-6.03%+34.66%+31.95%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
0.00%+26.12%+62.77%+73.92%-19.61%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
0.00%0.00%+1.64%+140.39%+152.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
0.7719 of 5 stars
1.30.00.00.01.94.20.6
Pharvaris N.V. stock logo
PHVS
Pharvaris
2.4204 of 5 stars
3.54.00.00.02.40.80.0
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.0389 of 5 stars
4.50.00.04.43.20.80.0
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
3.0876 of 5 stars
4.24.00.00.01.12.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
2.50
Moderate Buy$8.008.55% Upside
Pharvaris N.V. stock logo
PHVS
Pharvaris
3.00
Buy$35.6059.64% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
3.00
Buy$38.00141.42% Upside
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
2.33
Hold$14.5730.92% Upside

Current Analyst Ratings Breakdown

Latest LFCR, SNDX, PHVS, and VERV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$55.00 ➝ $52.00
8/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/5/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$46.00 ➝ $51.00
8/5/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$43.00 ➝ $56.00
7/15/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$37.00 ➝ $35.00
7/10/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00
6/27/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.50
6/26/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$28.00 ➝ $11.00
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$12.00
6/18/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$13.50
(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$128.87M2.14N/AN/A$0.37 per share19.92
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/A$4.00 per shareN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$23.68M57.26N/AN/A$1.83 per share8.60
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$32.33M30.69N/AN/A$5.83 per share1.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$145.24M-$3.36N/AN/AN/AN/A-69.09%-63.34%N/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/A

Latest LFCR, SNDX, PHVS, and VERV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/25/2025Q4 2025
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.09N/AN/AN/A$35.36 millionN/A
8/12/2025Q1 2025
Pharvaris N.V. stock logo
PHVS
Pharvaris
-$0.87-$0.94-$0.07-$0.94N/AN/A
8/7/2025Q4 2025
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 million
8/4/2025Q2 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
113.76
2.84
1.59
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
8.33
11.10
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.06
4.71
4.55
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/A
9.84
9.84

Institutional Ownership

CompanyInstitutional Ownership
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
Pharvaris N.V. stock logo
PHVS
Pharvaris
N/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
97.11%

Insider Ownership

CompanyInsider Ownership
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
32.20%
Pharvaris N.V. stock logo
PHVS
Pharvaris
11.84%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.10%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
19.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
69037.41 million25.36 millionOptionable
Pharvaris N.V. stock logo
PHVS
Pharvaris
3052.29 million46.10 millionNot Optionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11086.14 million82.61 millionOptionable
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
11089.14 million71.94 millionOptionable

Recent News About These Companies

Verve Therapeutics Announces Merger and Nasdaq Delisting
Biotech lab
3 Bullish Biotech Stocks With Explosive Growth Trends
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Lifecore Biomedical stock logo

Lifecore Biomedical NASDAQ:LFCR

$7.37 -0.05 (-0.67%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$7.37 0.00 (0.00%)
As of 08/15/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Pharvaris stock logo

Pharvaris NASDAQ:PHVS

$22.30 -0.69 (-3.00%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$22.25 -0.05 (-0.22%)
As of 08/15/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$15.74 +1.01 (+6.86%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$15.88 +0.15 (+0.92%)
As of 08/15/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Verve Therapeutics stock logo

Verve Therapeutics NASDAQ:VERV

$11.13 0.00 (0.00%)
As of 07/25/2025

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.